As of 2025-11-13, the Intrinsic Value of Vitrolife AB (VITR.ST) is 143.55 SEK. This VITR.ST valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 142.50 SEK, the upside of Vitrolife AB is 0.70%.
The range of the Intrinsic Value is 87.14 - 416.07 SEK
Based on its market price of 142.50 SEK and our intrinsic valuation, Vitrolife AB (VITR.ST) is undervalued by 0.70%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 87.14 - 416.07 | 143.55 | 0.7% |
| DCF (Growth 10y) | 100.36 - 442.58 | 159.41 | 11.9% |
| DCF (EBITDA 5y) | 66.67 - 130.02 | 97.42 | -31.6% |
| DCF (EBITDA 10y) | 81.29 - 152.88 | 114.52 | -19.6% |
| Fair Value | 16.28 - 16.28 | 16.28 | -88.58% |
| P/E | 98.12 - 153.22 | 123.33 | -13.5% |
| EV/EBITDA | 57.11 - 118.92 | 90.79 | -36.3% |
| EPV | 88.06 - 127.92 | 107.99 | -24.2% |
| DDM - Stable | 41.81 - 225.43 | 133.62 | -6.2% |
| DDM - Multi | 63.62 - 257.64 | 101.01 | -29.1% |
| Market Cap (mil) | 19,301.63 |
| Beta | 0.69 |
| Outstanding shares (mil) | 135.45 |
| Enterprise Value (mil) | 20,194.63 |
| Market risk premium | 5.10% |
| Cost of Equity | 6.38% |
| Cost of Debt | 5.38% |
| WACC | 6.15% |